Compare Amphastar Pharmaceuticals Inc (AMPH) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Otis Worldwide Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Otis Worldwide Corp trades at $73.45 (market cap $27.74B). The key difference: Otis Worldwide Corp is far larger — about 32.1× Amphastar Pharmaceuticals Inc's market cap, and Otis Worldwide Corp pays a 2.42% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | OTIS | |
|---|---|---|
Market Cap | $863.95M | $27.74B |
Sector | Health | Industrials |
52-Week High | $30.81 | $93.62 |
52-Week Low | $16.87 | $69.34 |
Enterprise Value | $1.26B | $35.77B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Otis Worldwide (OTIS) trades at $73.99, up 0.22% with a bullish technical signal. The company maintains stable revenue around $14.4B but faces margin pressure despite strong service segment growth. Recent Q2 2026 earnings beat estimates but included guidance cuts, reflecting ongoing challenges in new equipment demand. Analyst consensus remains divided with a $92.50 price target suggesting 25% upside potential.
The investment case hinges on service segment momentum offsetting equipment weakness, but margin compression and elevated debt levels pose risks. With mixed analyst ratings and recent institutional selling, the stock offers value if service margins improve, though execution risks remain elevated in the current economic environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
